ARTICLE | Clinical News

Velcade Phase II NSCLC data

June 7, 2004 7:00 AM UTC

An interim analysis of data from a Phase II trial of Millennium's Velcade bortezomib alone or in combination with Taxotere docetaxel as second line therapy in non-small cell lung cancer (NSCLC) patients showed that Velcade was active in both arms. In 29 patients receiving Velcade alone, there were three partial responses and five cases of stable disease. In 31 patients that received Velcade plus Taxotere, five had a partial response and 14 had stable disease. ...